Strategic Partnerships Target health systems and pediatric hospitals that treat cystic fibrosis, prematurity, and GI disorders to introduce RELiZORB and expanded-use capabilities, leveraging existing FDA-cleared indications to accelerate adoption.

Expansion Opportunities Position RELiZORB for broader enteral nutrition programs beyond pediatrics to adult populations with fat malabsorption, highlighting improved absorption of long-chain fatty acids to drive formulary placement and reimbursement discussions.

Clinical Evidence leveraged Leverage published clinical data and pivotal study results to support key value messages on improved nutrient absorption and caloric delivery, enabling stronger physician and payer conversations.

Key Leadership Engage with senior medical affairs and commercial leadership to accelerate education programs and clinical interoperability efforts, given recent appointive leadership additions and a growing medical affairs footprint.

Market Positioning Differentiate via an enzyme-based, in-line digestion solution with proven pediatric and adult applicability, and pursue partnerships with medical device distributors and enteral feeding manufacturers to broaden distribution and reel in capital-efficient growth.